Cargando…

SAT-237 Combined Bioidentical Estradiol and Progesterone Capsules Improved Quality of Sleep in Postmenopausal Women with Vasomotor Symptoms

Difficulty sleeping is a common complaint of postmenopausal women. In the REPLENISH trial, the oral 17β-estradiol/progesterone (E2/P4) softgel capsule (TX-001HR; 1 mg E2/100 mg P4 FDA approved as BIJUVA(TM); TherapeuticsMD, Boca Raton, FL), was shown to reduce moderate to severe hot flush frequency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoro, Nanette, Constantine, Ginger, Kagan, Risa, Graham, Shelli, Bernick, Brian, Mirkin, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551953/ http://dx.doi.org/10.1210/js.2019-SAT-237

Ejemplares similares

SAT-238 Predictors Of Vaginal/Uterine Bleeding With Oral TX-001HR (Estradiol and Progesterone) Capsules Taken For Menopausal Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2019)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

SAT-239 Bioidentical Estradiol and Progesterone Improved Hot Flushes, Night Sweats and Sweating
por: Liu, James, et al.
Publicado: (2019)

SAT-001 Clinically Meaningful Effects of E2/P4 Oral Capsule in Treating Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women
por: Kagan, Risa, et al.
Publicado: (2018)

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms
por: Constantine, Ginger D., et al.
Publicado: (2019)

SAT-LB003 Nonsmokers Benefit from Lower Doses of an Estradiol/Progesterone Combination: Results of the REPLENISH Trial
por: Constantine, Ginger, et al.
Publicado: (2019)

17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial
por: Kaunitz, Andrew M., et al.
Publicado: (2020)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms
por: Simon, James A., et al.
Publicado: (2019)

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)
por: Lobo, Rogerio A., et al.
Publicado: (2019)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone
por: Mirkin, Sebastian, et al.
Publicado: (2019)

Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial
por: Black, Denise R., et al.
Publicado: (2020)

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women
por: Constantine, Ginger D., et al.
Publicado: (2017)

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial
por: Liu, James H., et al.
Publicado: (2020)

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)(∗)
por: Mirkin, Sebastian, et al.
Publicado: (2020)

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR
por: Kingsberg, Sheryl A., et al.
Publicado: (2017)

SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
por: Liu, James H, et al.
Publicado: (2020)

SAT-219 A Novel 1-Year Contraceptive Vaginal System Delivering Segesterone Acetate and Ethinyl Estradiol: Effects on Lipids and other Hepatic Proteins
por: Archer, David, et al.
Publicado: (2019)

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol
por: Archer, David F., et al.
Publicado: (2017)

Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy
por: Pickar, James H., et al.
Publicado: (2015)

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial
por: Constantine, Ginger D., et al.
Publicado: (2020)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Systemic estradiol levels with low-dose vaginal estrogens
por: Santen, Richard J., et al.
Publicado: (2019)

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial
por: Simon, James A., et al.
Publicado: (2017)

MON-006 Progesterone Receptor Expression in Endometrial Biopsies After 12 Weeks of Exposure to A 4-µg E2 Softgel Vaginal Insert or Placebo
por: Simon, James A, et al.
Publicado: (2020)

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies
por: Stanczyk, Frank Z., et al.
Publicado: (2019)

Estradiol and progesterone levels in early pregnancy after natural, estradiol + progesterone or gonadotrophin stimulated frozen embryo transfer cycle: a randomised controlled trial protocol
por: Mørch, Nina Freiesleben, et al.
Publicado: (2022)

Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert
por: Mirkin, Sebastian, et al.
Publicado: (2021)

SAT-027 Comparison of Estradiol by Mass Spectrometry Versus Immunoassay in Women Undergoing Menopause: Study of Womens Health Across the Nation (SWAN)
por: Santoro, Nanette F, et al.
Publicado: (2020)

Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule
por: Pickar, J. H., et al.
Publicado: (2016)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

SAT-235 Severe Hyperandrogenemia in Postmenopausal Women as a Presentation of Ovarian Hypertheocosis
por: Ganta, Sandeep, et al.
Publicado: (2019)

Estradiol to progesterone ratio is not a predictor of oocyte maturity at time of ovulation trigger
por: Berger, Marisa, et al.
Publicado: (2022)

Progesterone Positive Feedback on Pulsatile LH Secretion and FSH Release May Be Blunted in Estradiol-Pretreated Women With PCOS
por: McCartney, Christopher Rolland, et al.
Publicado: (2021)

LBMON237 Predictors Of Postmenarchal Progression Of Pcos Phenotypes In At-risk Girls
por: Torchen, Laura C, et al.
Publicado: (2022)

Physical characteristics and properties of estradiol softgel vaginal inserts
por: Simon, James A., et al.
Publicado: (2019)

SAT-240 Type B Insulin Resistance Resulting in Hyperthecosis in a Postmenopausal Woman
por: Bedoya, Pablo, et al.
Publicado: (2019)

SAT384 Is This A Case of Androgen-Secreting Endometrial Cancer in A Postmenopausal Woman?
por: Taqi, Vian, et al.
Publicado: (2023)

SAT-210 Autoimmune Progesterone Dermatitis: A Rare Case Report in a Young Woman with Chronic Dermatitis
por: Elsheikh, Arwa
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4aejsddn60ffm2mett7j350c7r